Company: CNTB
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001835268-25-000058
Chunk: 54

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 8
Chunk 54
---
, introducing significant U.S. tax changes. Key provisions of the OBBBA include changes to bonus depreciation, capitalized research and development expenditures and interest deductibility. The OBBBA did not have a material impact on the Company’s effective tax rate or consolidated financial statements for the three and nine months ended September 30, 2025.

19

12. Segment Reporting

The Company operates in one operating segment: treatment of respiratory diseases. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the Chief Operating Decision-Maker (the “CODM”), our Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The CODM utilizes the Company’s consolidated financial forecast, which includes product development roadmaps, as a key input to resource allocation. The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results using our operating expenses, cash burn and cash runway.The following table provides significant segment expenses, other segment items, reported segment net loss and a reconciliation of segment net loss to the Company’s total consolidated net loss for the three and nine months ended September 30, 2025 and 2024 (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2025202420252024License and collaboration revenue$16 $1,219 $64 $25,335 Research and development expense(11,110)(9,009)(26,516)(23,020)General and administrative expense(6,583)(6,056)(16,096)(15,148)Other income, net538 1,027 2,347 6,228 Income tax expense(61)(57)(170)(117)Segment net loss(17,200)(12,876)(40,371)(6,722)Reconciliation of loss:Adjustments and reconciling items— — — — Consolidated net loss$(17,200)$(12,876)$(40,371)$(6,722)The Company’s long-lived tangible assets, as well as the Company’s ROU lease assets recognized on the Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 were located as follows: $0.8 million and $0.1 million, respectively, in the U.S. and $3.9 million and $4.1 million, respectively, in the PRC.